New look at antiplatelet agent-related peptic ulcer: An update of prevention and treatment

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 4, 2012, Pages 654-661

  Hsu, Ping I ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antiplatelet agent; Aspirin; Bleeding; Clopidogrel; Drug interaction; Peptic ulcer

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ESOMEPRAZOLE; FAMOTIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; TICLOPIDINE;

ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; HELICOBACTER INFECTION; HUMAN; INFECTION RISK; LOW DRUG DOSE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SECONDARY PREVENTION; UPPER GASTROINTESTINAL BLEEDING;

EID: 84858843470     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07085.x     Document Type: Article

References (54)

1. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch. Intern. Med. 2002; 162: 2197-202.
2. Pearson TA, Blair SN, Daniels SR etal. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American heart association science advisory and coordinating committee. Circulation 2002; 106: 388-91.
3. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among US adults: behavioral risk factor surveillance system. Am. J. Prev. Med. 2006; 30: 74-7.
4. Cryer B, Feldman M. Effects of very low doses of daily, long-term aspirin therapy on gastric, duodenal and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25.
5. Ng W, Wong WN, Chen WH etal. Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J. Gastroenterol. 2006; 12: 2923-7.
6. Gent M, Blakely JA, Easton JD etal. The Canadian American Ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-20.
7. Chan FKL, Ching JYL, Hung LCT etal. Clopidogrel versus aspirin and esomeprazole for the prevention of recurrent ulcer bleeding. N. Engl. J. Med. 2005; 352: 238-44.
8. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatry 1991; 54: 1044-54.
9. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127: 395-402.
10. Yeomans ND, Lanas AI, Talley NJ etal. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin aliment. Pharmacol. Ther. 2005; 22: 795-801.
11. Boeynaems JM, van Giezen H, Savi P, Herbert JM. P2Y receptor antagonist in thrombosis. Curr. Opin. Investig. Drugs 2005; 6: 257-82.
12. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-39.
13. Hsu PI, Lai KH, Lau CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011; 140: 791-8.
14. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of edostatin and vascular endothelial growth factor release. Proc. Natl. Acad. Sci. U.S.A. 2001; 98: 6470-5.
15. Sung JJ, Lau JY, Ching JY etal. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann. Intern. Med. 2010; 152: 1-9.
16. Komatsu T, Tamai Y, Takami H etal. Study for determination of the optimal cessation period of therapy with antiplatelet agents prior to invasive endoscopic procedures. J. Gastroenterol. 2005; 40: 698-707.
17. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk for ischemic stroke. Neurology 2004; 62: 1187-9.
18. Hsu PI, Lin XZ, Chan SH etal. Bleeding peptic ulcer-risk factors for rebleeding and sequential changes in endoscopic findings. Gut 1994; 35: 746-9.
19. Hsu PI, Lai KH, Lin XZ etal. When to discharge patients with bleeding peptic ulcers-a prospective study of residual risk of rebleeding. Gastrointest. Endosc. 1996; 44: 382-7.
20. Ng SC, Chan FKL. NSAID-induced gastrointestinal and cardiovascular injury. Curr. Opin. Gastroenterol. 2010; 26: 611-17.
21. Sostres C, Lanas A. Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding? Drugs 2011; 71: 1-10.
22. Grines CL, Bonow RO, Casey DE Jr etal. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American college of Surgeons, and American Dental Association, with representation from the American College of Physicians. J. Am. Coll. Cardiol. 2007; 49: 734-9.
23. Schouten O, van Domburg RT, Bax JJ etal. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J. Am. Coll. Cardiol. 2007; 49: 122-4.
24. Hsu PI. Esomeprazole plus aspirin compared with esomeprazole alone for the treatment of aspirin-related peptic ulcers/erosions. Gastroenterology 2011; 140 (Suppl.): S79.
25. Anderson JL, Adams CD, Antman EM etal. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Circulation 2007; 116: e138-304.
26. Ng FH, Wong BCY, Wong SY etal. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk-a single-blind, randomized controlled study. Aliment. Pharmacol. Ther. 2004; 19: 356-65.
27. Gilard M, Arnaud B, Cornily JC etal. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized double-blind OCLA (Omeprazole Clopidogrel Asprin) study. J. Am. Coll. Cardiol. 2008; 51: 256-60.
28. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am. J. Gastroenterol. 2010; 105: 34-41.
29. US Food and Drug Administration. Early Communication about an Ongoing Safety Review of Clopidogrel Bisulfate (Marketed as Plavix). Cited May 2009. Available from URL:
30. European Medicines Agency. Public Statement on Possible Interaction Between Clopidogrel and Proton Pump Inhibitors. Cited May 2009. Available from URL:
31. Fock KM, Katelaris P, Sugano K etal. Second Asia-Pacific Conference. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009; 24: 1587-600.
32. Chan FKL. Managing NSAID-induced ulcer complications-balancing gastrointestinal and cardiovascular risks. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006; 3: 563-73.
33. Cryer B. Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterol. Clin. North Am. 2009; 38: 289-303.
34. Bhatt DL, Scheiman J, Abraham NS etal. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. J. Am. Coll. Cardiol. 2008; 52: 1502-17.
35. Lai KC, Lam SK, Chu KM etal. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002; 346: 2033-8.
36. Yeomans N, Lanas A, Labenz J etal. Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am. J. Gastroenterol. 2008; 103: 2465-73.
37. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119-25.
38. Ng FH, Wong SY, Lam KF etal. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010; 138: 82-8.
39. Lanas A, Garci{dotless}a-Rodri{dotless}guez LA, Arroyo MT etal. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 2007; 102: 507-15.
40. Ng FH, Wong SY, Chang CM etal. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment. Pharmacol. Ther. 2003; 18: 443-9.
41. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and proton pump inhibitors. Ann. Pharmacother. 2009; 43: 1266-74.
42. Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin. Pharmacokinet. 2008; 47: 1-6.
43. Abelo A, Andersson TB, Antonsson M etal. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. 2000; 28: 966-72.
44. Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin. Ther. 2000; 22: 1268-93.
45. Sibbing D, Morath T, Stegherr J etal. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 2009; 101: 714-19.
46. Angiolillo DJ, Gibson CM, Cheng S etal. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin. Pharmacol. Ther. 2011; 89: 65-74.
47. Ferreiro JL, Ueno M, Tomasello SD etal. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ. Cardiovasc. Interv. 2011; 4: 273-9.
48. Small DS, Farid NA, Payne CD etal. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol. 2008; 48: 475-84.
49. Ho PM, Maddox TM, Wang L etal. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
50. Juurlink D, Gomes T, Ko DT etal. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-18.
51. Kreutz RP, Stanek EJ, Aubert R etal. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcome study. Pharmacotherapy 2010; 30: 787-96.
52. Burkard T, Kaiser CA, Brunner-La Rocca H etal. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J. Intern. Med. 2011; doi: 10.1111/j.1365-2796.2011.02423.x. [Epub ahead of print].
53. Chen M, Wei JF, Xu YN etal. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. Cardiovasc. Ther. 2011; doi: 10.1111/j.1755-5922.2011.00289.x. [Epub ahead of print].
54. Bhatt DL, Cryer BL, Contant CF etal. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 2010; 363: 1909-17.